JPMorgan Initiates Coverage on MBX Biosciences with 'Overweight' Rating

MBX Biosciences (NASDAQ:MBX) has received positive coverage from investment analysts at JPMorgan Chase & Co., who initiated coverage on the stock with an 'overweight' rating and a price target of $88.00.

This would represent a potential upside of 32.09% from the current price, according to MarketBeat's data.

The report joins other analysts who have also weighed in on MBX Biosciences, including Barclays, UBS Group, Citigroup, and Citizens Jmp, among others.